FASENRA®
FASENRA® (Benralizumab) is an immunosuppressive drug that is used as an add-on maintenance therapy for patients with severe Eosinophilic Asthma.
FASENRA® is manufactured by AstraZeneca.
Administration and Dosage:
Administration of FASENRA® follows an induction regimen of 3 subcutaneous injections every 4 weeks followed by a maintenance injection, once every 8 weeks.
Indication:
FASENRA® is indicated to treat:
- Add-on Maintenance for Severe Eosinophilic Asthma
Common Side Effects:
The more common side effects of FASENRA® include allergic (hypersensitivity) reactions, including anaphylaxis.
More information:
Please read the full Prescribing Information and Instructions for Use for FASENRA® and discuss any questions you have with your doctor.
HAVE QUESTIONS?
We are happy to help!
